Use of a Liver-Specific Promoter Reduces Immune Response to the Transgene in Adenoviral Vectors
- 20 July 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (11) , 1773-1781
- https://doi.org/10.1089/10430349950017455
Abstract
Previous studies using adenoviral (Ad) vectors expressing human alpha1-antitrypsin (hAAT) under the control of ubiquitous promoters (RSV, mPGK) elicited the production of antibodies to hAAT in some mouse strains (C3H/HeJ and BALB/c) but not in others (C57BL/6J). In contrast, when a helper-dependent Ad vector (AdSTK109) with all viral coding sequences deleted and expressing hAAT from human genomic DNA with the endogenous promoter was used, C3H/HeJ mice failed to develop antibodies and demonstrated long-term expression. These results suggested that promoter choice and/or properties of the vector itself might influence the host immune response to the transgene product. Direct comparison of first-generation vectors expressing the hAAT cDNA from a ubiquitous mouse PGK promoter rather than from a liver-specific mouse albumin promoter demonstrated that an antibody response to hAAT occurred with the mPGK promoter but not with the albumin promoter in C3H/HeJ mice. As expected, neither vector elicits an antibody response in C57BL/6J mice. Coinjection of the two first-generation vectors containing the mPGK and albumin promoter in C3H/HeJ mice induced an antibody response with resulting loss of detectable hAAT from the sera of the injected mice in 3-4 weeks. From these data, we conclude that under certain conditions, the choice of promoter with its associated liver-specific expression can modulate the host immune response to the transgene independent of viral backbone.Keywords
This publication has 47 references indexed in Scilit:
- Toxicological Comparison of E2a-Deleted and First-Generation Adenoviral Vectors Expressingα1-Antitrypsin after Systemic DeliveryHuman Gene Therapy, 1998
- A Phase I Study of Adenovirus Mediated Gene Transfer of Interleukin 2 cDNA into Metastatic Breast Cancer or Melanoma. The Toronto Hospital, Toronto, Ontario, CanadaHuman Gene Therapy, 1997
- Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors FollowingIn VivoAdministrationHuman Gene Therapy, 1997
- Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice.The Journal of Experimental Medicine, 1996
- High-Level Tissue-Specific Expression of Functional Human Factor VIII in MiceHuman Gene Therapy, 1996
- Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2aHuman Gene Therapy, 1994
- Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosisNature Genetics, 1994
- Gene Therapy for Cystic Fibrosis Using E1-Deleted Adenovirus: A Phase I Trial in the Nasal Cavity. University of North Carolina at Chapel Hill, Chapel Hill, North CarolinaHuman Gene Therapy, 1994
- Adenovirus mediated expression of therapeutic plasma levels of human factor IX in miceNature Genetics, 1993
- Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.Journal of Clinical Investigation, 1993